Novartis AG
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About Novartis AG
Novartis develops and manufactures innovative drugs. Key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
/ 
Novartis AG (NOVN) is a Swiss multinational pharmaceutical company headquartered in Basel, Switzerland. Formed in 1996 through the merger of Ciba-Geigy and Sandoz, Novartis is one of the world's largest healthcare companies, focused on innovative medicines.
The company's activities centre on research, development, manufacturing, and marketing of prescription medicines across therapeutic areas such as oncology, immunology, neuroscience, and cardiovascular/renal diseases.
With a global presence, Novartis invests heavily in biotechnology, advanced therapies, and digital health solutions. The group continues to expand its portfolio through innovation and strategic partnerships, addressing unmet medical needs worldwide.
Novartis AG is listed on the SIX Swiss Exchange.
